



Australian Government
Department of Health
Therapeutic Goods Administration

Public Summary

Summary for ARTG Entry:	308511	RestoraCalm
ARTG entry for	Medicine Listed	
Sponsor	FIT-BioCeuticals Limited	
Postal Address	Care of Blackmores Ltd PO Box 1725, Warriewood, NSW, 2102 Australia	
ARTG Start Date	22/08/2018	
Product Category	Medicine	
Status	Active	
Approval Area	Listed Medicines	

Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified of the report or reports.

The sponsor shall not supply the listed medicine after the expiry date of the goods.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

Products

1 . RestoraCalm

Product Type	Single Medicine Product	Effective Date	22/08/2018
---------------------	-------------------------	-----------------------	------------

Permitted Indications

Traditionally used in Western herbal medicine to decrease/reduce/relieve restlessness/excess nervous energy

Decrease/reduce/relieve symptoms of stress

Traditionally used in Western herbal medicine to decrease/reduce/relieve symptoms of stress

Traditionally used in Western herbal medicine to decrease/reduce/relieve nervous tension/unrest

Decrease/reduce/relieve symptoms of mild anxiety in pre-menopausal women

Traditionally used in Western herbal medicine to decrease/reduce/relieve symptoms of mild anxiety

Traditionally used in Western herbal medicine to nervine/support nervous system

Support healthy emotional/mood balance

Traditionally used in Western herbal medicine to decrease/reduce/relieve disturbed/restless sleep

Indication Requirements

Label statement: If symptoms persist, talk to your health professional.

Product presentation must not imply or refer to mental illnesses, disorders or conditions.

Product presentation must only refer to mild anxiety.

Standard Indications

No Standard Indications included on Record

Specific Indications

No Specific Indications included on Record

Warnings



Australian Government
Department of Health
Therapeutic Goods Administration

No Warnings included on Record

Additional Product information

Pack Size/Poison information

Pack Size

Poison Schedule

Components

1 . Formulation 1

Dosage Form Tablet, film coated

Route of Administration Oral

Visual Identification

Active Ingredients

Magnolia officinalis	68.75 mg
Passiflora incarnata herb top flowering and fruiting Extract dry concentrate	50 mg
Equivalent: Passiflora incarnata (Dry)	500 mg
Phellodendron amurense	22.5 mg
Scutellaria lateriflora herb Extract dry concentrate	250 mg
Equivalent: Scutellaria lateriflora (Dry)	1 g

Other Ingredients (Excipients)

calcium hydrogen phosphate dihydrate
Carnauba Wax
chlorophyllin-copper complex
colloidal anhydrous silica
croscarmellose sodium
high amylose maize starch
hypromellose
macrogol 8000
magnesium stearate
maize starch
maltodextrin
microcrystalline cellulose
powdered cellulose
silicon dioxide

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary